Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.34, Iss.2, 1998-02, pp. : 155-162

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metabolism of Fibric Acid Derivatives

By Spence J.D.

Clinical Pharmacokinetics, Vol. 34, Iss. 5, 1998-05 ,pp. : 419-420

Adis International

Access to resources Recommend Favorite

Statins, fibric acid derivatives reduce risk of dementia

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Role of Fibric Acid Derivatives in the Management of Risk Factors for Coronary Heart Disease

By Jean-Pierre Després Isabelle Lemieux

Drugs, Vol. 64, Iss. 19, 2004-01 ,pp. : 2177-2198

Adis International

Access to resources Recommend Favorite

The use of fibric acid derivatives combined with rosiglitazone appears to decrease HDL cholesterol levels in patients with diabetes mellitus (DM)

Reactions Weekly, Vol. 1, Iss. 1184, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

An increased number of reports of psychiatric reactions occurring with fibric acid derivatives, statins and ezetimibe have been received

Reactions Weekly, Vol. 1, Iss. 1128, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite